Intellia Therapeutics NTLA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's accrued expenses?
- Intellia Therapeutics (NTLA) reported accrued expenses of $37.92M in Q1 2026.
- How has Intellia Therapeutics's accrued expenses changed year-over-year?
- Intellia Therapeutics's accrued expenses decreased by 7.1% year-over-year, from $40.81M to $37.92M.
- What is the long-term trend for Intellia Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Intellia Therapeutics's accrued expenses has grown at a 14.3% compound annual growth rate (CAGR), from $25.55M to $49.86M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.